Brink Therapeutics
Paris, FR · Founded 2024 · 11 employees on LinkedIn · 3 known investors
Find your way into Brink Therapeutics
215 people in our graph share verified history with the Brink Therapeutics team — schools, employers, funds. One of them is your warm intro.
Logan Hilleunlockedknows Jonathan Naccache · together at Harvard University (overlapped)
knows the team · via Detect
×3knows the team · via SUEZ
×2knows the team · via Harvard University
×2knows the team · via INSEAD
×2knows the team · via INSERM UNIT UMR-S 1193
Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.
Founders & leadership
Brink Therapeutics was founded in 2024 by Jonathan Naccache.
JN
Jonathan NaccacheinCo-founder (Directeur de la publication)Jonathan Naccache holds a Ph.D. from ESPCI (PSL) and an MBA from INSEAD Business School, and is co-founder of Brink Therapeutics, a company developing programmable integrases for genomic insertion in cell and gene therapy applications.
H
HarryinFounder
A
Andrew
Investors · 3
Competitors · 5
by search overlap
Stingraytx3 shared keywordsStingray is an oncology-focused biotech company developing drugs from discovery through clinical development to commercialization, led by scientists and physicians with experience in building oncology companies.
virion3 shared keywordsVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Relay3 shared keywordsRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
Remix Therapeutics3 shared keywordsRemix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders. The company applies precision medicine approaches across oncology and other therapeutic areas.
Aro Biotherapeutics3 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Companies competing with Brink Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Brink Therapeutics do?
- Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.
- Who founded Brink Therapeutics?
- Brink Therapeutics was founded by Jonathan Naccache in 2024.
- Who are Brink Therapeutics's investors?
- Brink Therapeutics's investors include Kima Ventures, Breega, Kurma Partners.
- Where is Brink Therapeutics headquartered?
- Brink Therapeutics is headquartered in Paris, FR.